financetom
Business
financetom
/
Business
/
Olink Swings to Q4 Net Loss, Revenue Rises
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Olink Swings to Q4 Net Loss, Revenue Rises
Mar 25, 2024 6:00 AM

08:42 AM EDT, 03/25/2024 (MT Newswires) -- Olink Holding ( OLK ) reported a Q4 net loss Monday of $0.06 per diluted share, swinging from net income of $0.05 a year earlier.

Three analysts polled by Capital IQ expected earnings of $0.16.

Revenue for the quarter ended Dec. 31 was $68.6 million, up from $57.9 million a year earlier.

Four analysts surveyed by Capital IQ expected $89.9 million.

Olink ( OLK ) said the Swedish Inspectorate of Strategic Products has cleared Thermo Fisher Scientific's (TMO) planned acquisition of the company and that it expects the deal to be completed by mid-2024.

Olink ( OLK ) shares were up 1.7% in recent Monday premarket activity.

Price: 24.73, Change: +0.42, Percent Change: +1.73

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Amazon Wants Workers Back in Office 5 Days a Week
--Amazon Wants Workers Back in Office 5 Days a Week
Sep 16, 2024
01:41 PM EDT, 09/16/2024 (MT Newswires) -- Price: 184.50, Change: -1.99, Percent Change: -1.07 ...
Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity
Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity
Sep 16, 2024
Over the weekend, Nuvalent, Inc ( NUVL ). highlighted the presentation of updated data from Phase 1 dose-escalation portions of the ongoing ARROS-1 Phase 1/2 trial of zidesamtinib and ALKOVE-1 Phase 1/2 trial of NVL-655, at the European Society for Medical Oncology (ESMO) Congress 2024. In total, 227 patients were enrolled in the Phase 2 portion of the ARROS-1 trial of zidesamtinib...
Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition
Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition
Sep 16, 2024
Psyence Biomedical Ltd. ( PBM ) , a biotechnology company focused on creating natural psychedelic-based solutions to address mental health challenges, has issued an update to shareholders, highlighting significant recent developments and upcoming milestones. The company has initiated a Phase IIb clinical trial in Australia to evaluate psilocybin-assisted therapy for Adjustment Disorder in palliative care. Results are expected in late...
What's Going On With Exicure Shares Monday?
What's Going On With Exicure Shares Monday?
Sep 16, 2024
Exicure, Inc. ( XCUR ) stock is trading higher on Monday after the company entered into debt-for-equity exchange agreements. What Happened: On Friday, Exicure ( XCUR ) filed a Form 8-K with the Securities and Exchange Commission that signaled that it entered into debt-for-equity agreements with DGP and another with a separate individual. DGP, Exicure’s largest shareholder, holds about 35%...
Copyright 2023-2026 - www.financetom.com All Rights Reserved